Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Disproportionate reporting signal workbook arrived with a competitor label that just got a narrower indication for labeling negotiator. That is a Pharma & Life Sciences Pharmacovigilance decision on to drop a secondary in a company with a CMC site change mid-review.

DECISION Labeling negotiator in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. The population in disproportionate reporting signal workbook is the one a competitor label that just got a narrower indication named, so Proceed under protocol follows for this Pharmacovigilance file. 2. The population in disproportionate reporting signal workbook is adjacent only to a competitor label that just got a narrower indication; Pause the pathway is the honest Pharma & Life Sciences call. 3. A company with a CMC site change mid-review already contained a competitor label that just got a narrower indication before disproportionate reporting signal workbook arrived; no new Pharmacovigilance path. 4. Provenance on disproportionate reporting signal workbook after a competitor label that just got a narrower indication is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether disproportionate reporting signal workbook supports the labeled claim labeling negotiator would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a competitor label that just got a narrower indication and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for labeling negotiator in a company with a CMC site change mid-review.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in disproportionate reporting signal workbook, then the action for labeling negotiator - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in disproportionate reporting signal workbook that a second reviewer can re-perform